Overview

Our History

Leadership Team

Partner

Portfolio Advisory Board

Peer Reviewed Publications

Announcements and Circulars

Listing Documents

Investor Presentation

IR Contact

Investor Calendar

Stock Information (2552.HK)

Corporate Communications

Our Science

Peer Reviewed Publications

Prediction of HMS5552 human pharmacokinetics using Allometric Scaling, IVIVE,Css-MRT and PBPK Modeling Methods （2016 中国药理学会定量药理学专业委员会年会）

2016 Chinese Pharmacological Society

Hua Medicine

Jan 01, 2016

8499

Online link unavailable, presentation available upon request. (BD@huamedicine.com)

Return list

Clinical Proof of Concept (POC) of Glucokinase Activator HMS5552 Achieved in Chinese T2DM Patients: HbA1c Reduction of 1.22% with 100% Response Rate and Improved β-cell Function

Clinically Differentiated Glucokinase Activator HMS5552: Effective Control of 24-Hour Glucose and Improvement of β Cell Function in T2DM Patients

About Us

Overview

Our History

Leadership Team

Portfolio Advisory Board

Partner

Media center

Research & Development

Inovation

Dorzagliatin

mGluR5

Presentations

Peer Reviewed Publications

Media

Company News

Media Releases

Video

Investor Relations

Corporate Governance

Financial Report

Announcements & Circulars

Listing Documents

Investor Presentation

IR Contact

Investor Calendar

Stock information

Careers

Culture

Join Us

Products&Pipeline

Pipeline

HuaTangNing(华堂宁®)

Focus Us

沪公网安备 31011502013809号 Privacy Statement Terms of Use

How we use cookies

Hua Medicine uses cookies to enable and improve the use of the website. By continuing to use the site, you consent to the use of these cookies. To learn more about cookies, please read our privacy statement.